论文信息 - A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. - 字舞流文

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.

O. Frankfurt | R. Stone | G. Bollag | M. Levis | J. Pagel | Catherine C. Smith | G. Roboz | Chao Zhang | E. Wang | A. Perl | B. Lam | B. West | P. Severson | S. Kayser | M. Le | H. Hsu